Health · Pharma & Biotech · 51 mins ago
Beam shares early data on rare-disease gene-editing therapy
Beam Therapeutics shared initial trial data for a gene-editing treatment being developed for a rare disease.
The data came from a Phase 1/2 clinical trial, an early stage of testing.
Beam suggests its treatment may correct the mutation behind the disease.
The information provided does not say how many people took part or what results they had.
Separately, Pfizer plans to collaborate with Enodia, though the collaboration's focus is not specified.
No further steps or timing were given.
Beam Therapeutics shared initial data from a Phase 1/2 trial of a rare-disease gene-editing therapy.
The company’s early data suggest the therapy can correct a mutation.
The report did not identify the disease or provide trial results in the available text.
- Who
- Beam Therapeutics.
- What
- It shared initial data from a Phase 1/2 trial of a rare-disease gene-editing therapy.
- When
- October 13, 2026.
- Where
- Not stated.
- Why
- Not stated.
This story does not have two clearly opposing sides.
This story does not have a timeline yet.
- Company
- Beam Therapeutics
- Trial phase
- Phase 1/2
- Data
- Initial data on a rare-disease gene-editing therapy
- Date
- October 13, 2026
Sources
Related news
BioNTech cancer vaccine misses one goal in pivotal trial
At least 90 lawsuits allege weight-loss drugs caused vision loss
Syndax ends Niktimvo development for lung disease after Phase 2 failure
Early research links GLP-1 drugs to signs of slower biological aging
Experts raise safety concerns about Neurocrine’s Prader-Willi drug
US FDA supports planned trial of StemSmart therapy for Crohn’s disease
UCLA specialists outline how doctors can choose between two MASH drugs
Bimatoprost eye lens shows early promise for cataracts and glaucoma
Italian Registry Study Finds Avacopan Appeared Effective for AAV
Resmetirom Linked to Lower Heart Risks Than Semaglutide in Liver Disease Analysis
Merck’s eye drug meets main study goal, but results are mixed
